Ex Vivo News and Research

RSS

Researchers patent biomaterial that generates artificial bones from umbilical cord stem cells

Scientists in Granada, Spain, have patented a new biomaterial that facilitates generating bone tissue-artificial bones in other words-from umbilical cord stem cells . The material, consisting of an activated carbon cloth support for cells that differentiate giving rise to a product that can promote bone growth, has recently been presented at a press conference at the Biomedical Research Centre, Granada.

19 Jul 2013

Cancer immunotherapies promise to be a new tool in fight against cancer

Drugs that direct a cancer patient's immune system to eradicate her or his disease, known as cancer immunotherapies, promise to be a new tool in the fight against cancer. Since the Koch Institute's inception, exploring the close relationship between the immune system and cancer has been one of the Institute's priority research areas.

9 Jul 2013

RetroNectin reagent now available for gene therapy clinical research

In an effort to aid progress in gene therapy clinical research, representatives of Clontech laboratories, Inc. and its parent company Takara Bio Inc. announce the availability of clinical grade RetroNectin reagent for direct supply to biomedical researchers.

17 Jun 2013

Researchers issue statement regarding use of unproven stem cell therapies

An international group of leading stem cell researchers has issued a statement that specifies concerns about the development and use of unproven stem cell therapies.

4 May 2013

BioLineRx starts enrollment in Phase I/II trial of BL-8020 for treatment of HCV

BioLineRx, a biopharmaceutical development company, announced today enrollment of the first patient in a Phase I/II trial for BL-8020, an orally available, interferon-free treatment for the Hepatitis C virus.

29 Apr 2013

Opsona raises €33M in oversubscribed financing round

Opsona Therapeutics Limited, the innate immune drug development company, today announced that it has raised €33 million (US $ 43 million) in an oversubscribed Series C financing.

29 Apr 2013

Perosphere, Daiichi Sankyo sign clinical trial agreement

Perosphere Inc. and Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced today that they have entered into a clinical trial agreement under which Daiichi Sankyo will support and co-sponsor a phase 1 clinical study testing the safety, tolerability and effectiveness of PER977 to reverse the anticoagulant activity of edoxaban, Daiichi Sankyo's investigational oral, once-daily, direct factor Xa-inhibitor.

25 Apr 2013

Changing parameters used to deliver RF treatment greatly affects size of resulting heat lesion

Changing the parameters used to deliver radiofrequency treatment greatly affects the size of the resulting heat lesion, researchers reported today in a study expected to deliver greater precision and more treatment options in interventional pain management.

15 Apr 2013

EMA designates Osiris as Orphan Drug title holder for Prochymal

Osiris Therapeutics, Inc., the leading stem cell company developing and marketing products to treat medical conditions in inflammatory, cardiovascular, orthopedic and wound healing markets, announced today that the European Medicines Agency (EMA) has designated Osiris as the Orphan Drug title holder for Prochymal (remestemcel-L).

19 Feb 2013

Gamida Cell announces results from NiCord Phase I/II study on hematological malignancies

Gamida Cell announced today the successful results of the Phase I/II study of its second pipeline product NiCord, umbilical cord derived stem cells expanded using the company's proprietary NAM technology.

15 Feb 2013

Sucampo receives supplement approval from FDA for AMITIZA

Sucampo Pharmaceuticals, Inc. today announced that the Company received a supplement approval from the U.S. Food and Drug Administration (FDA) that removes pregnancy "warnings and precautions" and clarifies information regarding the use of AMITIZA (lubiprostone) by pregnant and/or nursing women. In addition, the FDA expanded the labeling text of the Mechanism of Action section in the prescribing information for AMITIZA.

30 Nov 2012

TransMedics closes $36 million financing round

TransMedics, Inc., the global leader in organ preservation technology, announced the closing of a $36 million financing round led by Abrams Capital with the participation of existing investors including Flagship Ventures, Hercules Technology Growth Capital and Kleiner Perkins Caufield & Byers.

27 Nov 2012

Functional profiling using EVA/PCD doubles response rate and improves survival in NSCLC patients

Functional profiling using ex-vivo analysis of programmed cell death (EVA/PCD) doubles the response rate and improves time-to-progression and survival in patients with advanced lung cancer, according to a Phase II clinical trial conducted by investigators at Rational Therapeutics and the MemorialCare Todd Cancer Institute and published in the October issue of Anticancer Research.

8 Oct 2012

CytoDyn announces update on feline immunodeficiency virus therapeutic antibody program

CytoDyn Inc., a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, announced today that it is presenting an update on its Feline Immunodeficiency Virus (FIV) therapeutic antibody program at the 19th West Coast Retrovirus meeting in Palm Springs, California.

8 Oct 2012

Life Technologies receives FDA clearance for OpTmizer CTS T-cell expansion media

Life Technologies Corporation today announced it has received FDA 510(k) clearance for its OpTmizer CTS T-Cell Expansion Tissue Culture Medium – a reagent that is now cleared as a Class II medical device and offers cost- and time-saving advantages for transitioning studies from the research bench to clinical trials.

28 Sep 2012

Wiley announces publication of 6-volume Encyclopedia of Drug Metabolism and Interactions

Wiley is pleased to announce publication of the state-of-the-art, 6-volume Encyclopedia of Drug Metabolism and Interactions.

25 Sep 2012

MU endocrinologist to receive American Heart Association lifetime achievement award

One of the first researchers to study the deadly link between cardiovascular disease and diabetes will receive an American Heart Association lifetime achievement award today at a ceremony in Washington, D.C. The award presented to University of Missouri endocrinologist James Sowers, MD, recognizes his more than 30 years of accomplishments as a physician, scientist and educator.

21 Sep 2012

Enrollment complete in Gamida Cell’s NiCord Phase I/II trial for hematological malignancies

Gamida Cell, a leader in adult stem cell expansion technologies and products, announced today that it has completed enrollment for a Phase I/II clinical trial of NiCord, the company's second pipeline product.

20 Sep 2012

New results describe development of DC cancer vaccine with enhanced immunogenic potential

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, and collaborators at Radboud University Nijmegen Medical Centre in the Netherlands announced today that they have published new pre-clinical results in the journal Cancer Immunology Immunotherapy describing the development of a dendritic cell (DC) cancer vaccine with enhanced immunogenic potential.

23 Aug 2012

Arteriocyte receives NIH grant for use of NANEX platform in bone marrow transplant

Arteriocyte, a leading clinical stage biotechnology company developing cellular based therapies to treat human diseases, announced today the successful award of another grant by the National Institute of Health for the use of the NANEX platform in Hematopoietic Reconstitution Using Ex Vivo Expanded Umbilical Cord Blood CD34+ Stem Cells.

22 Aug 2012